Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jee H. Choe; Hisham Abdel-Azim; William V. Padula; Mohamed Abou-El-Enein

doi:10.1001/jamanetworkopen.2022.45956

Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jee H. Choe, Hisham Abdel-Azim, William V. Padula, Mohamed Abou-El-Enein

Pediatric Hematology/Oncology Division

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	e2245956
Journal	JAMA Network Open
Volume	5
Issue number	12
DOIs	https://doi.org/10.1001/jamanetworkopen.2022.45956
State	Published - Dec 15 2022

ASJC Scopus Subject Areas

General Medicine

Access to Document

10.1001/jamanetworkopen.2022.45956

OpenUrl availability

Full text

Cite this

@article{e571cb4bc737418ab5741bdd4c2d00c9,

title = "Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma",

author = "Choe, {Jee H.} and Hisham Abdel-Azim and Padula, {William V.} and Mohamed Abou-El-Enein",

year = "2022",

month = dec,

day = "15",

doi = "10.1001/jamanetworkopen.2022.45956",

language = "English",

volume = "5",

journal = "JAMA Network Open",

issn = "2574-3805",

number = "12",

}

TY - JOUR

T1 - Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

AU - Choe, Jee H.

AU - Abdel-Azim, Hisham

AU - Padula, William V.

AU - Abou-El-Enein, Mohamed

PY - 2022/12/15

Y1 - 2022/12/15

UR - http://www.scopus.com/inward/record.url?scp=85144227357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85144227357&partnerID=8YFLogxK

U2 - 10.1001/jamanetworkopen.2022.45956

DO - 10.1001/jamanetworkopen.2022.45956

M3 - Article

C2 - 36520440

AN - SCOPUS:85144227357

SN - 2574-3805

VL - 5

JO - JAMA Network Open

JF - JAMA Network Open

IS - 12

M1 - e2245956

ER -

Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ASJC Scopus Subject Areas

Access to Document

OpenUrl availability

Other files and links

Cite this